The Top 5 Biosimilar Articles for the Week of May 5

Number 5: The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key challenges, including a lack of data in CD and opportunities to improve access to treatment.

Number 4: Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.

Number 3: Sarfaraz K. Niazi, PhD, discusses US Senator Rand Paul's Expedited Access to Biosimilars Act, which aims to streamline the biosimilar approval process by eliminating redundant clinical study requirements, potentially lowering drug prices and improving access to life-saving treatments.

Number 2: Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

Number 1: A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.

To read all of these articles and more, visit centerforbiosimilars.com.